近日，世界著名学术出版商斯普林格（Springer）发布消息，宣布撤回旗下期刊《肿瘤生物学（TumorBiology）》发表于2012年至2016年的107篇论文，原因是同行评议造假。107篇论文全部来自中国，创下了正规学术期刊单次撤稿数量的纪录...丢人还还还...破纪录 了(名单附后)。
“论文提交的评审人意见中，使用了评审人的真实姓名，但假冒了其电子邮件地址，这让编辑以为文章发送给了真正的评审人。在我们与真正的评审人进行调查和沟通之后，他们确认并没有对论文做过评审。”
A new record: Major publisher retracting more than 100 studies from cancer journal over fake peer reviews
Springer is retracting 107 papers from one journal after discovering they had been accepted with fake peer reviews[1]. Yes, 107.
[1]peer review:the process of someone reading, checking, and giving his or her opinion about something that has been written by another scientist or expert working in the same subject area, or a piece of work in which this is done 同行评审/评议；同级评审
All these papers have been published after being subjected to peer review.
To submit a fake review, someone (often the author of a paper) either makes up an outside expert to review the paper, or suggests a real researcher - and in both cases, provides a fake email address that comes back to someone who will invariably give the paper a glowing review. In this case, Springer, the publisher of Tumor Biology through 2016, told us that an investigation produced “clear evidence” the reviews were submitted under the names of real researchers with faked emails. Some of the authors may have used a third-party editing service, which may have supplied the reviews. The journal is now published by SAGE.
为了提交假的评审意见，某人（通常是论文作者）在推荐审稿人时，或者杜撰一个外部专家，或者推荐一名真的研究者——但两种情况下，都会提供一个假的邮箱地址，这些邮箱会指向一个必然会高度赞许那篇论文的人。 在本次事件中，《肿瘤生物学》（Tumor Biology）2016年的出版商施普林格告诉我们，调查报告给出了“明显证据”证明这些评审意见是以真实研究者的名义，通过虚假的邮箱提交的。有些作者可能使用了第三方编辑服务，评审意见可能来自这些服务商。 目前，《肿瘤生物学》期刊的出版商已经改为赛吉（SAGE）出版公司。
The retractions follow another sweep by the publisher last year, when Tumor Biology retracted 25 papers forcompromised review and other issues, mostly authored by researchers based in Iran. With the latest bunch of retractions, the journal has now retracted the most papers of any other journal indexed by Clarivate Analytics' Web of Science, formerly part of Thomson Reuters. In 2015, its impact factor[影响因子] - 2.9 - ranked it 104th out of 213 oncology journals[肿瘤学期刊/杂志].
该出版社去年已经有过一次"清扫行动"了，当时《肿瘤生物学》因为评审意见不合标准及其他原因撤回了25篇论文，大部分是由来自伊朗的研究人员撰写的。加上这最新一轮的撤稿，所有收录在科睿唯安Web of Science数据库（原为汤森路透业务）的期刊当中，《肿瘤生物学》是至今撤过论文数最多的期刊了。2015年，这一期刊的影响因子为2.9，在213家肿瘤学期刊中排名第104位。
Here's more from Springer's official statement, out today:
After the retractions as a result of fake peer review (amongst others) in 2015 and 2016 that involved Tumor Biology, the decision was made to screen[审查,调查;筛选] new papers before they are released to production. Based on this extra screening, new names of fake reviewers were detected and in order to clean up our scientific records, we will now start retracting these affected articles.
2015年和2016年因虚假同行评审等原因导致的撤稿涉及《肿瘤生物学》期刊，在那以后，施普林格决定在发表新的论文前对它们进行检查。根据这次额外查验，我们发现了一批新的虚假审稿人名单，为了维护我们的学术声誉，我们现在将要开始撤回这批相关论文。
The current retractions are not a new case of integrity breach but are the result of a deeper manual investigation which became necessary after our previous retractions from Tumor Biology in 2016. The extent of the current retractions was not obvious from the earlier investigations in 2015. We are retracting these published papers because the peer-review process required for publication in our journals had been deliberately compromised by fabricated[伪造的;捏造的] peer reviewer reports.
本次撤稿并非是一轮新的违反诚信案例，而是一次深入的人工调查的结果。在2016年撤回《肿瘤生物学》的部分论文后，这样的深入调查就变得很有必要。更早的调查发生在2015年，当时并未察觉问题的规模有如此之广。我们正在撤回这些已经发表的论文。因为我们期刊发表所要求的同行评审流程已经被这些伪造的同行评审报告蓄意破坏。
英文原文：
翻译参考：@果壳网
附名单如下：
- 每天持续行动学外语
- 关注微信公众号：LearnAndRecord，带你轻松学外语
选择“Disable on www.wenxuecity.com”
选择“don't run on pages on this domain”
